124
Participants
Start Date
August 16, 2013
Primary Completion Date
February 10, 2020
Study Completion Date
February 10, 2020
Pasireotide LAR
60 mg was administered as an intra muscular depot injection once every 28 days starting at Day 1
Everolimus
10 mg tables administered orally once a day
Pasireotide LAR and Everolimus Combination
Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
Novartis Investigative Site, Orbassano
Novartis Investigative Site, Berlin
Novartis Investigative Site, Granada
Novartis Investigative Site, Milan
Novartis Investigative Site, Brescia
Novartis Investigative Site, Madrid
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Oviedo
Novartis Investigative Site, Rennes
Novartis Investigative Site, Padua
Novartis Investigative Site, Seville
Novartis Investigative Site, Parma
Novartis Investigative Site, Valencia
Novartis Investigative Site, Mainz
Novartis Investigative Site, Lille
Novartis Investigative Site, Ancona
Novartis Investigative Site, Strasbourg
Novartis Investigative Site, Lyon
Novartis Investigative Site, Napoli
Novartis Investigative Site, Créteil
Novartis Investigative Site, Villejuif
Novartis Investigative Site, Viagrande
Novartis Investigative Site, Bad Berka
Novartis Investigative Site, Aarhus
Novartis Investigative Site, Copenhagen N
Novartis Investigative Site, Athens
Novartis Investigative Site, Perugia
Novartis Investigative Site, Roma
Novartis Investigative Site, Amsterdam
Novartis Investigative Site, Groningen
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Lund
Novartis Investigative Site, Withington
Novartis Investigative Site, Glasgow
Novartis Investigative Site, London
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY